Atossa Therapeutics’ Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Atossa Therapeutics (ATOS – Research Report). The associated price target remains the same with $4.00.

Jason McCarthy has given his Buy rating due to a combination of factors related to Atossa Therapeutics’ promising developments and potential in the oncology field. His optimism is driven by the progress of Atossa’s Endoxifen programs, which are showing potential as effective treatments for various breast cancer indications. McCarthy notes that the oral (Z)-endoxifen is moving forward in phase 2 trials with positive data outcomes, such as a 100% disease control rate and significant lesion size reduction, as evidenced by recent presentations at medical conferences. This is significant when compared to existing treatments, as Atossa’s Endoxifen is demonstrating rapid attainment of therapeutic levels, which can be crucial in the neoadjuvant setting.

The analyst also highlights several promising studies, including the EVANGELINE study, which is a phase 2 trial comparing Endoxifen to standard-of-care treatments in a neoadjuvant setting for pre-menopausal women with certain types of breast cancer. The quick buildup of therapeutic levels of Endoxifen, in contrast to the slower process associated with tamoxifen, represents a potential advantage in treatment efficacy. Additionally, the completion of enrollment in other phase 2 trials and the commencement of new study arms suggest strong momentum in Atossa’s clinical programs. These factors, combined with a healthy cash runway, underpin McCarthy’s positive rating for Atossa Therapeutics’ stock.

According to TipRanks, McCarthy is an analyst with an average return of -16.9% and a 28.78% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inmune Bio, and Indaptus Therapeutics.

In another report released yesterday, H.C. Wainwright also assigned a Buy rating to the stock with a $6.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Atossa Therapeutics (ATOS) Company Description:

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.